Pat Mitchell

728 total citations
23 papers, 560 citations indexed

About

Pat Mitchell is a scholar working on Oncology, Surgery and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Pat Mitchell has authored 23 papers receiving a total of 560 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 6 papers in Surgery and 6 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Pat Mitchell's work include Antiplatelet Therapy and Cardiovascular Diseases (6 papers), Lipoproteins and Cardiovascular Health (6 papers) and CAR-T cell therapy research (3 papers). Pat Mitchell is often cited by papers focused on Antiplatelet Therapy and Cardiovascular Diseases (6 papers), Lipoproteins and Cardiovascular Health (6 papers) and CAR-T cell therapy research (3 papers). Pat Mitchell collaborates with scholars based in United States, United Kingdom and Singapore. Pat Mitchell's co-authors include Dennis W. Schneck, Paul Martin, Kathleen Butler, Renli Teng, Rongyue Teng, Steven G. Simonson, Kenneth C. Lasseter, Mike J. Warwick, Ann S. LaCasce and Nancy L. Bartlett and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

Pat Mitchell

22 papers receiving 548 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Pat Mitchell United States 14 195 149 146 77 71 23 560
Vana Kolovou Greece 17 242 1.2× 166 1.1× 97 0.7× 24 0.3× 53 0.7× 49 673
Yi‐Heng Li Taiwan 14 291 1.5× 313 2.1× 34 0.2× 50 0.6× 56 0.8× 67 752
Paweł Burchardt Poland 16 176 0.9× 320 2.1× 107 0.7× 38 0.5× 18 0.3× 86 798
Guangyan Mu China 11 99 0.5× 143 1.0× 47 0.3× 20 0.3× 20 0.3× 52 383
JL Anderson United States 4 65 0.3× 226 1.5× 113 0.8× 31 0.4× 60 0.8× 6 693
Roelof W. F. van Leeuwen Netherlands 16 142 0.7× 59 0.4× 508 3.5× 54 0.7× 67 0.9× 37 1.2k
S. Unger Germany 10 180 0.9× 168 1.1× 257 1.8× 38 0.5× 31 0.4× 19 724
Yuan‐Lin Guo China 14 286 1.5× 202 1.4× 62 0.4× 58 0.8× 21 0.3× 54 561
T. Eisenhauer Germany 14 438 2.2× 192 1.3× 51 0.3× 62 0.8× 41 0.6× 38 789
Cesare Alessandri Italy 17 313 1.6× 175 1.2× 71 0.5× 111 1.4× 11 0.2× 29 1.1k

Countries citing papers authored by Pat Mitchell

Since Specialization
Citations

This map shows the geographic impact of Pat Mitchell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pat Mitchell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pat Mitchell more than expected).

Fields of papers citing papers by Pat Mitchell

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pat Mitchell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pat Mitchell. The network helps show where Pat Mitchell may publish in the future.

Co-authorship network of co-authors of Pat Mitchell

This figure shows the co-authorship network connecting the top 25 collaborators of Pat Mitchell. A scholar is included among the top collaborators of Pat Mitchell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pat Mitchell. Pat Mitchell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hamilton, Erika, Judy S. Wang, Amit M. Oza, et al.. (2023). First-in-human Study of AZD5153, A Small-molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and Lymphoma. Molecular Cancer Therapeutics. 22(10). 1154–1165. 14 indexed citations
2.
Hwang, Ji Won, Diansong Zhou, Carine Paturel, et al.. (2023). Population Pharmacokinetics of Monalizumab in Patients With Advanced Solid Tumors. The Journal of Clinical Pharmacology. 63(7). 817–829.
3.
Moorthy, Ganesh, Gayle P. Pouliot, Lorraine Graham, et al.. (2020). Abstract CT168: Clinical pharmacology of AZD4635 (A2ARi): Integration of PK data from cancer patients (CP) and healthy volunteer (HV) clinical trials to provide dosing recommendations. Cancer Research. 80(16_Supplement). CT168–CT168. 1 indexed citations
4.
Bendell, Johanna C., Todd M. Bauer, Manish R. Patel, et al.. (2019). Abstract CT026: Evidence of immune activation in the first-in-human Phase Ia dose escalation study of the adenosine 2a receptor antagonist, AZD4635, in patients with advanced solid tumors. Cancer Research. 79(13_Supplement). CT026–CT026. 20 indexed citations
5.
6.
Mitchell, Pat, Bengt Hamrén, Gabriel Helmlinger, et al.. (2018). Integrating dose estimation into a decision‐making framework for model‐based drug development. Pharmaceutical Statistics. 17(2). 155–168. 1 indexed citations
7.
Cullberg, Marie, Cecilia Arfvidsson, Bengt Larsson, et al.. (2018). Pharmacokinetics of the Oral Selective CXCR2 Antagonist AZD5069: A Summary of Eight Phase I Studies in Healthy Volunteers. Drugs in R&D. 18(2). 149–159. 19 indexed citations
8.
9.
10.
Flinn, Ian W., Nancy L. Bartlett, Kristie A. Blum, et al.. (2015). A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). European Journal of Cancer. 54. 11–17. 61 indexed citations
11.
Teng, Rongyue, Pat Mitchell, & Kathleen Butler. (2014). The effect of desmopressin on bleeding time and platelet aggregation in healthy volunteers administered ticagrelor. Journal of Clinical Pharmacy and Therapeutics. 39(2). 186–191. 33 indexed citations
12.
Teng, Renli, Pat Mitchell, & Kathleen Butler. (2013). Evaluation of the pharmacokinetic interaction between ticagrelor and tolbutamide, a cytochrome P450 2C9 substrate, in healthy volunteers. International Journal of Clinical Pharmacology and Therapeutics. 51(4). 305–312. 6 indexed citations
13.
Teng, Renli, Pat Mitchell, & Kathleen Butler. (2012). Pharmacokinetic interaction studies of co-administration of ticagrelor and atorvastatin or simvastatin in healthy volunteers. European Journal of Clinical Pharmacology. 69(3). 477–487. 53 indexed citations
14.
Teng, Renli, Pat Mitchell, & Kathleen Butler. (2012). Effect of age and gender on pharmacokinetics and pharmacodynamics of a single ticagrelor dose in healthy individuals. European Journal of Clinical Pharmacology. 68(8). 1175–1182. 26 indexed citations
15.
Teng, Renli, Pat Mitchell, & Kathleen Butler. (2012). Effect of rifampicin on the pharmacokinetics and pharmacodynamics of ticagrelor in healthy subjects. European Journal of Clinical Pharmacology. 69(4). 877–883. 29 indexed citations
16.
Teng, Rongyue, Pat Mitchell, & Kathleen Butler. (2011). Lack of significant food effect on the pharmacokinetics of ticagrelor in healthy volunteers. Journal of Clinical Pharmacy and Therapeutics. 37(4). 464–468. 17 indexed citations
17.
Schneck, Dennis W., et al.. (2008). Population pharmacokinetics of rosuvastatin: implications of renal impairment, race, and dyslipidaemia. Current Medical Research and Opinion. 24(9). 2575–2585. 35 indexed citations
18.
Simonson, Steven G., et al.. (2005). Effect of Rosuvastatin on Warfarin Pharmacodynamics and Pharmacokinetics. The Journal of Clinical Pharmacology. 45(8). 927–934. 40 indexed citations
19.
Simonson, Steven G., Paul Martin, Mike J. Warwick, Pat Mitchell, & Dennis W. Schneck. (2004). The effect of rosuvastatin on oestrogen & progestin pharmacokinetics in healthy women taking an oral contraceptive. British Journal of Clinical Pharmacology. 57(3). 279–286. 23 indexed citations
20.
Martin, Paul, Pat Mitchell, & Dennis W. Schneck. (2002). Pharmacodynamic effects and pharmacokinetics of a new HMG‐CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers. British Journal of Clinical Pharmacology. 54(5). 472–477. 126 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Vana Kolovou Breakdown of academic impact, for papers by Yi‐Heng Li Breakdown of academic impact, for papers by Paweł Burchardt Breakdown of academic impact, for papers by Guangyan Mu Breakdown of academic impact, for papers by JL Anderson Breakdown of academic impact, for papers by Roelof W. F. van Leeuwen Breakdown of academic impact, for papers by S. Unger Breakdown of academic impact, for papers by Yuan‐Lin Guo Breakdown of academic impact, for papers by T. Eisenhauer Breakdown of academic impact, for papers by Cesare Alessandri
Rankless by CCL
2026